BlackRock’s Rani Therapeutics RANI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$260K Sell
342,113
-214,776
-39% -$190K ﹤0.01% 4746
2026
Q1
$409K Buy
556,889
+29,177
+6% +$37.3K ﹤0.01% 4583
2025
Q4
$712K Buy
527,712
+407,480
+339% +$615K ﹤0.01% 4397
2025
Q3
$60.1K Buy
120,232
+1,580
+1% +$823 ﹤0.01% 4949
2025
Q2
$61K Buy
118,652
+55,069
+87% +$44.9K ﹤0.01% 4953
2025
Q1
$80.1K Hold
63,583
﹤0.01% 4821
2024
Q4
$87.1K Hold
63,583
﹤0.01% 4816
2024
Q3
$137K Hold
63,583
﹤0.01% 4610
2024
Q2
$242K Hold
63,583
﹤0.01% 4511
2024
Q1
$198K Hold
63,583
﹤0.01% 4582
2023
Q4
$211K Hold
63,583
﹤0.01% 4625
2023
Q3
$138K Hold
63,583
﹤0.01% 4771
2023
Q2
$262K Hold
63,583
﹤0.01% 4666
2023
Q1
$328K Hold
63,583
﹤0.01% 4648
2022
Q4
$375K Sell
63,583
-139,324
-69% -$1.02M ﹤0.01% 4685
2022
Q3
$1.94M Sell
202,907
-3,925
-2% -$41.6K ﹤0.01% 4213
2022
Q2
$2.14M Buy
206,832
+49,458
+31% +$568K ﹤0.01% 4230
2022
Q1
$2.13M Buy
157,374
+43,076
+38% +$715K ﹤0.01% 4363
2021
Q4
$1.87M Buy
+114,298
New +$2.6M ﹤0.01% 4428

Other funds holding RANI

BlackRock's RANI Position: Q2 2026 in Review

BlackRock reduced its Rani Therapeutics (RANI) stake by 39% in Q2 2026, selling an estimated $190K and leaving 342,113 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #4746.

BlackRock first reported a position in RANI in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.14M in Q2 2022. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • BlackRock held 342,113 shares of Rani Therapeutics worth $260K as of Q2 2026.
  • BlackRock sold 214,776 Rani Therapeutics shares in Q2 2026, an estimated $190K.
  • Rani Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4746 holding.
  • BlackRock first reported a position in Rani Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Rani Therapeutics position peaked at $2.14M in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.